Disappearance of eyelid xanthelasma following oral simvastatin (Zocor)

The major risk factors for coronary heart disease include smoking, elevated blood pressure, and elevated serum cholesterol. Risk reduction starts with identification of those at risk and then alteration of factors such as discontinuation of smoking, lowering of blood pressure, and reduction of serum cholesterol. Patients who have had a blood cholesterol testing include those with family history of premature coronary heart disease or hyperlipidemia, personal history of coronary heart disease, or clinical evidence of elevated lipids with features of xanthelasma, corneal arcus under age 50 years, and cutaneous xanthomas at any age. One of the latter clinical features are ophthamlatic and detection relies on the ophthalmologist. Xanthelasma appear as multiple yellow placoid lesions in the periorcular skin and represent a concentration of lipocytes in the dermis. There are numerous methods to manage the cosmetic appearance of xanthelasma, which typically involves surgical excision or laser ablation. We report a novel approach to management using oral cholesterol lowering medication and patience.

Case report

In 1992, a 68 year old male smoker with a history of hypertension and elevated serum cholesterol was referred for evaluation of a newly diagnosed iris mass. On examination, the visual acuity was 20/20 in both eyes. The mass was diagnosed as a benign iris nevus and observation was advised. Coincident unilateral medial canthal and upper and lower eyelid xanthelasma were detected (fig 1A). The largest xanthelasma measured 16 mm in diameter. Observation was advised with tentative plan for surgical excision in the future. The patient was advised to continue his antihypertensive medications and anticholesterol medication (oral simvastatin (Zocor) 20 mg once daily). At the 6 month follow up the iris nevus was stable and the xanthelasma persisted. Yearly examinations were advised. The patient did not return for 10 years. Surprisingly, the xanthelasma had completely resolved, leaving no clinical trace of subcutaneous lipid (fig 1B). He continued on his medications and serum cholesterol was normal.

Comment

In the Lipids Research Clinics Program Prevalence Study, xanthelasma and corneal arcus were associated with increased levels of serum cholesterol and low density lipoprotein cholesterol (LDL-C), especially in young men. People with either lesion had increased odds of having type IIa dyslipoproteinemia. Adjusted odds ratios for ischaemic heart disease in participants with xanthelasma and corneal arcus were generally increased. The study concluded that the clinical findings of xanthelasma or corneal arcus, especially in young people, helped to identify those with plasma lipoprotein abnormalities.

Management of patients with elevated LDL-C include both low cholesterol diet and cholesterol lowering medications, the most popular of which are the statins. There are currently five statin drugs on the market in the United States and these include lovastatin (Mevacor, Altocor), simvastatin (Zocor), pravastatin (Pravachol), fluvastatin (Lescol), and atorvastatin (Lipitor). The major effect of these medications is to lower LDL-C by slowing down the production of cholesterol and by increasing the liver’s ability to metabolise the LDL-C in the blood. Statins reduce LDL-C by approximately 40% and produce a modest increase in high density lipoprotein-cholesterol (HDL-C). These medications are given daily in the evening to take advantage of the fact that the body makes more cholesterol at night. Statins reduce measured blood LDL-C within 4–6 weeks. In a study of 20 536 patients, this resulted in long term reduction in coronary heart disease, stroke, and mortality.

Simvastatin is derived synthetically from a fermentation product of Aspergillus terreus. Simvastatin is hydrolysed to an inhibitor of an enzyme responsible for cholesterol synthesis. In the Multicenter Anti-Atheroma Study, simvastatin slowed the progression of atherosclerosis, measured by vascular stenosis diameter on angiography, and decreased significantly the development of new lesions.

To our knowledge, there have been no previous reports on the effect of statins on eyelid xanthelasma. A PubMed search for keywords “statin and xanthelasma” and simvastatin and xanthelasma yielded no relevant publications. The management of eyelid xanthelasma includes surgical excision, microsurgical inverted peeling, laser inverted resurfacing, photodynamic therapy using carbon dioxide laser, and application of bichloracetic acid. Patients with the highest recurrence rate are those with elevated cholesterol. These local treatments do not affect possible systemic associations. By observations in this report, we suggest that serum cholesterol be evaluated and if elevated, oral statin combined with dietary cholesterol restriction might result in resolution of xanthelasma over time, but, more importantly, reduction of patient cardiac risk.

C L Shields, A Mashayekhi, J A Shields
Ocular Oncology Service, Wills Eye Hospital, Thomas Jefferson University, Philadelphia, PA, USA

P Racciato
Pocono Medical Center, Stroudsburg, PA, USA

Correspondence to: Carol L Shields, MD, Ocular Oncology Service, Wills Eye Hospital, 840 Walnut Street, Philadelphia, PA 19107, USA; carol.shields@wills Eye.com
doi: 10.1136/bjo.2004.053058

Accepted for publication 13 September 2004

Support provided by the Eye Tumor Research Foundation, Philadelphia, PA (CLS), the Macula Foundation, New York, NY (CLS), the Rosenthal Award of the Macula Society (CLS), and the Paul Kayser International Award of Merit in Retina Research, Houston TX (JAS).

References


New onset diplopia: 14 years after retinal detachment surgery with a hydrogel scleral buckle

In 1979, the hydrogel explant (Mirage, Waltham, MA, USA) was introduced as a scleral buckling material in the surgical management of retinal detachment.1 It was widely used in the 1980s and early 1990s as it was initially believed to be well tolerated, less prone to infection, and easy to manipulate.2 However, long term complications related to swelling and fragmentation of the explant have been reported over recent years, resulting in discontinuation of its use in 1995.

Case report

A 36 year old man presented on 2003 with symptoms of mild right ocular discomfort. Past ocular history included a right retinal detachment repair 14 years previously, using a 907 (3 x 5 mm) Mirage scleral buckle (Mirage, Medical Instruments Research Associates, Waltham, MA, USA), sutured to the inferior sclera. On examination, visual acuity was 20/120 right and 20/20 left. There was no diplopia or limitation of eye movements. What was thought to be a small conjunctival cyst was noted inferioiy but, otherwise, the ocular examination was unremarkable and the retina was reattached.

A year later (2004), he presented with increasing marked right ocular discomfort and diplopia in all fields. His visual acuity was unchanged, but there was marked restriction of elevation and reduction in adduction of the right eye and binocular diplopia in all fields of gaze. A tense swelling of the inferior conjunctiva was noted (fig 1, top), intraocular pressure was normal, and the retina was flat with a moderate anterior chamber cell. What was thought to be a small conjunctival cyst was noted inferiorly but, otherwise, the ocular examination was unremarkable and the retina was reattached.

In our case, there was a profound increase in the explant volume during a 14 year period. The resulting diplopia and restriction of extraocular movement as well as the clinical examination mimicked a giant orbital inclusion cyst. The correct diagnosis was only made intraoperatively. Scleral thinning and necrosis as seen in our case has been reported previously,7 resulting in intraoperative vitreous leak after removal of the expanded explant.8 In our patient, there was an area of thinned sclera, but the surrounding calcification and the early removal of the explant prevented vitreous leak.

It is important to note that patients who have undergone scleral buckling with hydrogel explants before 1995 are at risk of developing this complication. Symptoms of progressive diplopia, pain, and restriction of extraocular muscle movement in these patients should also raise the possibility of explant expansion. The assistance of a retinal surgeon may sometimes be required because of the increased risk of scleral thinning and leakage of liquid vitreous intraoperatively.

I Leibovitch, J Crompton, D Selva
Oculoplastic and Orbital Unit, Department of Ophthalmology, Royal Adelaide Hospital, University of Adelaide, South Australia, Australia

Correspondence to: Dinesh Selva Oculoplastic and Orbital Unit, Department of Ophthalmology, Royal Adelaide Hospital, North Terrace, Adelaide, 5000, South Australia, Australia; Awestwoo@mail.rah.sa.gov.au
doi: 10.1136/bjo.2004.053868
Accepted for publication 27 August 2004

References


Inverse globe retraction syndrome complicating recurrent pterygium

Often larger and more aggressive than the original lesion, recurrent pterygium can cause visual symptoms that are most often secondary to their mechanical effects on the cornea.9 We report a case of inverse globe retraction syndrome (that is, retraction during abduction) due to the restrictive effect of a recurrent pterygium and the management of this complication.

Case report

A 28 year old man without a medical history or ocular symptoms underwent pterygium excision in his left eye with a superotemporal conjunctival autograft and intraoperative mitomycin C. Three weeks postoperatively, he noted a feeling of pressure in the left eye.
diplopia nor globe retraction during left gaze. The patient's feeling of presbyopia was relieved and there is neither.

Two months following the first procedure, the patient's feeling of presbyopia was relieved and surgery was scheduled.

Intraoperatively forced ductions showed –1 rectus abnormality,1° innervation disirection,1° and secondary to restriction from traumatic tissue capture in the medial orbital wall.1° The current case demonstrates another cause for the syndrome, globe restriction as a result of a leash effect from aggressive pterygium recurrence. The risk of pterygium recurrence after initial pterygium removal is minimised by the technique of conjunctival autograft with adjunctive mitomycin C; however, because aggressive recurrence is still possible initial pterygium surgery should only be performed for patients with significant cosmetic and/or functional concerns. For the management of inverse globe retraction syndrome complicating recurrent pterygium in this case, the use of amniotic membrane as a tissue spacer permitted excellent functional improvement.

Correspondence to: A O Khan, King Khalid Eye Specialist Hospital, PO Box 7191 Riyadh, Saudi Arabia; arif.khan@mssm.edu

References


Seeing is not believing

We describe a case of posterior cortical atrophy presenting with progressive visuo-perceptual and visuospatial difficulties, but with no abnormalities on standard ophthalmological examination.

Case report

The patient, a 53 year old right handed woman, with well controlled primary generalised epilepsy, presented to her optometrist with a 1 year history of deterioration in vision. She had particular difficulties with walking downstairs and following text while reading. She could read 6/12+2 RE (with −0.75−0.25+90 correction) and 6/12+3 (with −0.75+90 correction); LE. With +2.25 correction she could read N5 slowly with each eye. On subsequent ophthalmological review no significant abnormality was found on examination and no specific diagnosis was made.

Over the following months her vision deteriorated. She reported difficulties following a line while writing and was unable to tell when a glass was full when pouring a drink. Her husband thought that she was unable to see things in her peripheral vision. This culminated in her crashing her car. She did not have any memory difficulties, she had preserved insight, and there had been no change in personality.

On admission to our unit her visual acuity was 6/18 RE and 6/12 LE with the above correction. She was able to read slowly at N5 corrected with each eye but was unable to name any of the Ishihara plate numbers including the test plate, despite being able to name the colours, trace the outline of the numbers with her finger, and read numbers in normal print. Confrontation visual fields were essentially full although she was slow to recognise objects in her peripheral visual fields owing to an apparent narrowing of attention to foveal vision and had optic ataxia, in that she was unable to localise in space, by pointing, objects placed in her peripheral visual fields. On Goldmann perimeter her visual fields appeared somewhat constricted, probably related to her difficulties with attention, but, importantly, no homanopia was demonstrated (fig 1). Pupillary responses were normal as was fundal examination. On eye movement testing she had broken smooth pursuit eye movements, although she was able to generate voluntary saccades. The rest of the neurological examination was unremarkable.

Her mini-mental state examination score was 28/30. She had some deficits in verbal abstract reasoning and made occasional phonemic errors in speech. She had mild dyscalculia and dyspraxia, but she was able to differentiate left from right and name body parts. She had mild memory impairment, although these were mainly in tasks requiring visual input. She demonstrated simultagnosia in that she was unable to see the whole of a picture and only described parts of it.

On testing with the cortical vision screening test she passed the hue discrimination test, the word reading test, face perception test, the crowding test of letter reading and was able to detect the presence of a circle in the shape detection test but was unsure what to say if it was not present. On the symbol

Figure 1  Goldmann perimetry (V4e and II2e).

Figure 2 The patient’s appearance 6 weeks after amniotic membrane placement in (A) primary gaze, (B) right gaze, (C) left gaze. There is no longer globe retraction left eye during left gaze. During right gaze, adduction in the left eye occurs with less effort than that needed for abduction in the right eye.
which has been reported before in similar normal colour vision, is probably a reflection visuospatial ability, given her good, albeit acuity may have been related to her poor cognitive deficits. Her poor distance visual posterior cortical atrophy.

The CRVO, including retinal haemorrhages or macular oedema have vanished. The cilioretinal artery appears with physiological diameter.

The anterior segment in both eyes was normal. Magnetic resonance imaging demonstrated cerebral atrophy most marked in the both posterior parietal and occipital lobes (fig 2). A diagnosis of posterior cortical atrophy was made.

Comment

This woman therefore presented with progressive visuo-perceptual and visuospatial difficulties, but had no abnormalities on ophthalmological examination. She had some features of Balint’s syndrome (that is, simultanagnosia and optic ataxia) and other cognitive deficits. Her poor distance visual acuity may have been related to her poor visuospatial ability, given her good, albeit slow, near vision. Her inability to recognise any of the Ishihara plates, with otherwise normal colour vision, is probably a reflection of her other visuo-perceptual difficulties, which has been reported before in similar patients, although difficulty with figure-ground discrimination cannot be excluded.

Posterior cortical atrophy is a clinical and radiological diagnosis based upon the presence of occipitoparietal abnormalities with initially preserved occipitotemporal (face and colour recognition) and anterior cerebral function. It is thought to be a result of Alzheimer’s disease, in most cases, although the syndrome has been described with other pathologies—for example, subcortical gliosis, Creutzfeld-Jakob disease, and progressive multifocal leukoencephalopathy. Although it is rare, it should be suspected in any patient presenting with visuo-perceptual or visuospatial difficulties in the absence of any signs on standard ophthalmological examination. Screening tests for higher visual function deficits can then be employed.

The corollary of this is that a patient with an established diagnosis of dementia should be tested for disorders of higher visual function, because a patient with otherwise mild cognitive deficits may still be driving.

S J Hickman, D Alvarens, H Crewes, R J Wise, A N Gale
Royal Free Hospital, Pond Street, London NW3 2QG, UK

Correspondence to: Simon J Hickman, Royal Free Hospital, Pond Street, London NW3 2QG, UK; simonhickman@btinternet.com

doi: 10.1136/bjo.2004.054429

Accepted for publication 28 September 2004

References


Radial optic neurotomy in combined cilioretinal artery and central retinal vein occlusion

Combined cilioretinal artery and central retinal vein occlusion (CRVO) is a rare clinical finding first described by Oosterhuis. The pathogenesis of this condition is not well established and remains controversial. Most reports postulate that the initial CRVO causes an elevation of the intraluminal capillary pressure and induces a consecutively reduced perfusion pressure at the arterial side. Since the perfusion pressure of the cilio-retinal artery is lower than the central artery, it becomes relatively occluded. Recently Opremcak et al described radial optic neurotomy (RON) involving pars plana vitrectomy (PPV) and radial incision of the optic nerve to treat CRVO. We report this new surgical approach in a patient with combined cilioretinal artery occlusion and CRVO.

Case report

A healthy 64 year old woman complained of unilaterally blurred vision for the past 3 days. Her visual acuity (VA) was 20/200 in the right eye (RE) and 20/20 in the left eye (LE). The anterior segment in both eyes was unremarkable on slit lamp examination. Fundus examination revealed a whitening of the macula corresponding to an area supplied by a cilioretinal artery. The retinal veins were dilated, accompanied by adjacent retinal haemorrhages (fig 1A). The fundus of the left eye appeared normal. Fluorescein angiography (FA) RE revealed a delayed arteriovenous (AV) perfusion time of 13 seconds. Systemic evaluation of the patient did not reveal any general disease. Although treated systemically with corticosteroid and low dose heparin for 4 weeks, she developed CRVO with severe disc oedema, extensive dilatation of the retinal veins, radial orientated intraretinal haemorrhages, and cotton wool spots (fig 1B). On FA there was a reduced perfusion time of the cilio-retinal artery in addition to the typical
signs of CRVO (fig 2A). Based on positive results of RON in CRVO, we offered this treatment to our patient. After she signed an informed consent, RON was performed with two radial cuts at the nasal edge of the optic disc. After 2 days disc oedema was significantly reduced with sharp visible disc margins. Two months postoperatively the retinal haemorrhages, cotton wool spots, and disc oedema had disappeared and her VA improved to 20/25 RE (fig 1C). FA demonstrated a physiological AV perfusion time of less than 3 seconds and no signs of an occluded cilioretinal artery (fig 2B).

Comment
Combined cilioretinal artery occlusion and CRVO are discussed as a separate clinical entity in the literature,1,4 and its treatment by RON has not been described. Opremcak et al postulated that a surgical decompression of the optic disc and scleral ring by RON may contribute to an improved venous perfusion in CRVO. Our patient demonstrated additional signs of an arterial occlusion with delayed filling of the cilioretinal artery in the macula, which may induce permanent functional loss. The underlying pathomechanism of CRVO remain unknown, current discussion leans towards an intraluminal occlusion by a thrombus, increased extravasal pressure, or a combination of both as possible causes.2 In addition the therapeutic effect of RON is also questionable. It remains unclear as to whether RON causes a decompression of the optic disc increasing the ocular blood flow or induces the formation of new chorioretinal shunt vessel.3 In our case the goal of RON was to reduce the capillary pressure, therefore increasing the perfusion in the cilioretinal artery and thus improving central vision. Patients with combined occlusive AV disease may benefit from RON by improving their haemodynamic perfusion pressure, retinal anatomy, and consecutive central visual function.

5 Mennel, K Droutsas, C H Meyer, J C Schmidt, P Kroll
Department of Ophthalmology, Philipps-University Marburg, Germany

Correspondence to: Stefan Mennel, MD, Department of Ophthalmology, Philipps-University Marburg, Robert-Koch-Strasse 4, 35037 Marburg, Germany; stefan.mennel@lycos.com

doi: 10.1136/bjo.2004.054858
Accepted for publication 20 October 2004

Financial support: none.

Proprietary interest: none.

References

MAILBOX

Value based medicine

In a fine recent editorial, Drs Melissa and Gary Brown raised issues at the nexus of health policy and clinical science.1 As utility assessment is relatively new to the visual sciences, understanding both the assumptions behind this work and the consequences of relaxing those assumptions is essential for the conduct of high quality research and appropriate interpretation of the results. The use of community elicited utilities (that is, including people without the disease in the elicitation study) in economic evaluation should be given more than minimal consideration. Economic evaluations are intended to inform health policy makers by assessing the value society places on the cure or prevention of disease. Community based utilities typically reflect larger estimates of utility loss than those elicited from patients and result in a more favourable analysis than those relying on patient elicited utilities.2 At the same time, estimating community elicited utilities requires the development of easily understood scenarios to assist community members in understanding their role in the future, in the standard gamble the event is immediate. This provides an estimate of the person’s risk preference unconfounded by time. The time trade-off consistently results in a more favourable analysis of the cost-effectiveness of treatment or prevention.3

We hope that our comments will help future work to be pragmatic and theoretically sound. This is necessary if we are to properly characterise the appropriateness of our methods as well as the value of our findings.

S M Kymes
Washington University School of Medicine, Department of Ophthalmology and Visual Sciences, 660 South Euclid, Campus Box 8096, Saint Louis, MO 63116, USA

K D Frick
Johns Hopkins Bloomberg School of Public Health Department of Health Policy and Management, Baltimore, MD, USA

Correspondence to: Dr Steven Kymes, Washington University School of Medicine Department of Ophthalmology and Visual Sciences, 660 South Euclid, Campus Box 8096, Saint Louis, MO 63116, USA; kymes@wunc.wustl.edu

doi: 10.1136/bjo.2004.063784
Accepted for publication 3 December 2004
Cystoid macular oedema with trypan blue use

We read with interest the article by Gouws et al. on the apparent increased incidence of cystoid macular oedema (CMO) in phacoemulsification patients when trypan blue was used to stain the anterior capsule.

Trypan blue has been commonly used in cataract surgery to stain the anterior capsule and internal limiting membrane. The use of trypan blue has been associated with an increased incidence of cystoid macular oedema.

In a study by Landy et al., trypan blue use was associated with an increased incidence of posterior CMO. This finding has been supported by other studies, with some reporting a higher incidence of CMO when trypan blue is used compared to phacoemulsification alone.

However, it is important to note that the association between trypan blue use and CMO is not consistently replicated across studies. Some studies have not found a significant increase in CMO when trypan blue is used. The mechanism by which trypan blue may contribute to CMO is not fully understood, and further research is needed to clarify the role of trypan blue in the development of CMO.

In conclusion, while trypan blue use may be associated with an increased risk of CMO, the evidence is not conclusive. The decision to use trypan blue should be based on a careful consideration of the risks and benefits, taking into account the patient's individual needs and preferences.

References

Authors' reply
We thank Lam et al. for their interest. In response to their comment, as stated in the article and demonstrated in figures 1B and C, the effect persists when co-morbidity such as diabetes is removed.

Both groups’ surgery was performed by the same surgeon who did not have juniors attached to the list. Not all patients had dilated fundus examination postoperatively. Clinically significant cystoid macular oedema (CMO) is unlikely to be detected in patients with visual acuities of 6/12 or better, although subclinical CMO can be demonstrated in up to 20% with fluorescein angiography.
This retrospective study on a unique cohort of patients provided us with the opportunity to demonstrate a potential side effect with the use of trypan blue. A prospective trial is required to control for all the variables and confirm or refute our findings.

P Gow, P Simcock
Conquest Hospital, Hastings, UK

Correspondence to: Peter Simcock, West of England Eye Unit, Royal Devon and Exeter Hospital, Exeter EX2 5DW, UK; psimcock@hotmail.com
doi: 10.1136/bjo.2004.069765
Accepted for publication 23 February 2005

Reference


BOOK REVIEW

The History of Moorfields Eye Hospital, Volume III

Like John Mortimer’s book of a similar title this third volume of the history of Moorfields Eye Hospital is an affectionate but critical look back at the hospital that has been a major influence in many ophthalmologists’ training and subsequent practice. The volume is written in a positive upbeat style but also describes some of the faults and difficulties that have beset it in the past four decades. In a complex organisation such as a hospital there are inevitable inefficiencies and problems with personalities but the author has wisely stuck to the facts and has plotted the course of the management of the hospital in a very readable way; he has sensibly avoided petty confrontations and offers a lucid outline of the course of Britain’s flagship ophthalmic hospital.

The two previous histories of Moorfields described times past when ophthalmic practice changed only gradually and political upheaval was minor. The current author has been in the unique position of being involved with Moorfields throughout the 40 years he describes. Given the turmoil, both professional and managerial, that has engulfed the delivery of health care during this period he was fortunate that many of the individuals involved with the hospital were available for interview, thus providing first hand accounts of the good and bad times that affected the hospital. The various chapters outline lucidly the clinical and political changes of the time; Moorfields represents in microcosm all the influences to which NHS consultants of all disciplines have been subjected. One special feature of the period described is that it also covers the first 40 years following the foundation of the Institute of Ophthalmology and the not always easy relationship between the hospital and the institute is recorded both openly and tactfully.

The book comprises a number of chapters outlining the various aspects of the hospital development—for example, clinical, managerial, financial, etc. The first chapter is an overview involving all aspects of the hospital during the 40 years from 1963 to 2003. It provides a concise synopsis of all the forces bearing on the hospital; not only clinical but also in terms of research, teaching, and political upheaval. Indeed, for those younger ophthalmologists entering the profession at the present time, the book gives a concise overview of those political influences that have shaped the lives of the NHS and its staff during recent decades.

As the author points out in his preface the subsequent chapters take up the issues raised in the first chapter and analyse them in more detail. If one, therefore, picks up the book and reads it cover to cover there is a strong repetitive element but it was not really the author’s intention that the book should be necessarily read in this way. Each of the later chapters is written in a stand alone fashion dealing with clinical progress, academic development, research, teaching, and finance so that some repetition is inevitable. The major characters in the story of Moorfields development are given due weight; particularly Professor Barrie Jones, under whose influence Moorfields progressed from a rather slow moving organisation to the establishment of all the subspecialist services we know today.

Apart from rather a large number of nautical metaphors such as “calm waters,” “stormy seas,” and a few petty errors of detail, such as dates, this volume is a good read, particularly if approached as the author intended. He himself has made major contributions to the standing of Moorfields Eye Hospital and the book is written in the typically clear and polished style, reminiscent of his own scientific contributions.

R Grey
Bristol Eye Hospital, Lower Maudlin Street, Bristol BS1 2LX, UK; linda.clayton@uhsbt.swest.nhs.uk

NOTICES

Worldwide clinical trials for new technique for early detection of eye disease

A unique new non-invasive technique for high resolution optical imaging of the eye is receiving global acclaim. By combining two high-resolution imaging technologies, the new technique provides doctors with 3-D images of the retina, macula and the optic nerve.

For more information, contact the Media Office on 01227 823581/823100 or email MediaOffice@kent.ac.uk. News releases can also be found at: http://www.kent.ac.uk/news

Trachoma control

The latest issue of Community Eye Health (No 52) discusses new developments in the control of trachoma. For further information please contact: Journal of Community Eye Health, International Resource Centre, International Centre for Eye Health, Department of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, Keppel Street, London WC1E 7HT, UK (tel: +44 (0)20 7612 7964; email: Anita.Shahi@lshtm.ac.uk; online edition: www.jcch.co.uk). Annual subscription (4 issues) UK £28/US$45. Free to developing country applicants.

EVER 2005 meeting

This will take place on 5–8 October 2005 in Vilamoura, Portugal. For further details please contact: Christy Lacroix, EVER Secretary, Kapucijnenoever 33, B-3000 Leuven, Belgium (tel: +32 (0)16 233 849; fax +32 (0)16 234 097; email:ever@skynet.be).

World Ophthalmology Congress 2006 – Brazil

The World Ophthalmology Congress (which is replacing the International Congress of Ophthalmology) is meeting in February 2006 in Brazil.

For further information on the congress and committees, scientific program and coordinators of different areas are available at the congress website www.ophthalmology2006.com.br

CORRECTIONS

In the letter entitled, Norrie disease and peripheral venous insufficiency (Br J Ophthalmol 2004;88:1475) the ordering of the authors was incorrect. The correct order is Michaelides M, Luthert PJ, Cooling R, Firth H, Moore AT. The journal apologises for this error.

doi: 10.1136/bjo.2005.42556corr1

Owing to an author error the name of one of the authors of the paper entitled, Long term effect on IOP of a stainless steel glaucoma drainage implant (Ex-PRESS) in combined surgery with phacoemulsification, which appeared in the April issue of the journal (Br J Ophthalmol 2005;89:423–9) was omitted (S Gandolfi). The author list should be C Traverso, F De Feo, A Messas-Kapal, P Denis, S Levartovsky, E Sellem, F Badalà, Z Zagorski, A Bron, S Gandolfi, M Belkin. S Gandolfi is at the Clinica Ocucistica, University of Parma, Italy.

doi: 10.1136/bjo.2005.58032corr1